Detail akcie Omeros online

Business Summary: Omeros Corporation is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria, complement 3 (C3) glomerulopathy and one or more related indications.
Financial Summary: BRIEF: For the nine months ended 30 September 2023, Omeros Corp revenues was not reported. Net loss before extraordinary items increased less than 1% to $135.6M. Net income also reflects Interest and other income increase from $2.1M to $12.9M (income), Stock-based compensation expense decrease of 12% to $5.5M (expense), Stock-based Compensation in R&D decrease of 7% to $4.5M (expense).